SLShu-Peng Li

Shu-Peng Li

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Shu-Peng Li has a total of 15 co-authors. Here are the top co-authors by number of shared publications:

  • Dong Chen

    Institute of Cadio-Cerebrovascular Medicine, Dalian University of Technology, Dalian, China

    2 shared publications
  • Bohan Xi

    Department of Rehabilitation Beijing Rehabilitation Hospital of Capital Medical University Beijing China

    1 shared publication
  • Jia-Ming Huang

    Department of Neurosurgery, Central Hospital of Dalian University of Technology, Dalian, China

    1 shared publication
  • Jia-Wen Cui

    School of Biomedical Engineering, Faculty of Medicine, Dalian University of Technology, Dalian, China

    1 shared publication
  • Jiaming Huang

    Department of Neurosurgery Affiliated Dalian Municipal Central Hospital Dalian Medical University Dalian China

    1 shared publication
  • Jing-Lin Zhao

    Department of Cardiology, the Second Hospital of Dalian Medical University, Dalian, China

    1 shared publication

Latest Publications

  • Open Access

    Transcarotid Artery Revascularization for Asymptomatic Carotid Stenosis: A Systematic Review and Meta-Analysis

    by Zhi-Cheng Jiang, Qi-Fei Hu, Jia-Ming Huang, Xian-Wei Wang, Tong Lin, Xi-Lin Gao, Jia-Wen Cui, Jing-Lin Zhao, Dong Chen, Shu-Peng Li

    The online version contains supplementary material available at 10.1007/s12975-026-01457-2.

  • Open Access

    Integration of Single‐Cell RNA and Bulk RNA Sequencing Reveals Cellular Heterogeneity and Identifies Survival‐Associated Regulatory Networks in Glioblastoma

    by Zijun Xu, Bohan Xi, Jiaming Huang, Liqiang Zhang, Sifu Cui, Xianwei Wang, Dong Chen, Shupeng Li

    Glioblastoma is a highly aggressive and devastating brain malignancy with dismal prognosis and extremely limited therapeutic options. Identification of prognostic biomarkers and therapeutic targets from multi‐omics data is critical for improving patient outcomes. In this study, we investigated the clinical significance of cellular heterogeneity and super‐enhancer‐driven regulatory networks, which are critically implicated in glioblastoma progression and treatment resistance. We first performed scRNA‐seq to dissect tumour microenvironment heterogeneity, identifying 16 distinct cell clusters, including astrocytes, macrophages, and CD8+ T cells. CellChat analysis revealed key intercellular signalling pathways, with astrocytes and macrophages acting as central communication hubs. To integrate bulk RNA sequencing data, we applied the Scissor algorithm to identify survival‐associated cell states. By combining single‐cell and bulk transcriptomic data, we uncovered 642 survival‐related genes, including QKI and RBM47, which robustly predicted patient survival and immunotherapy response. Furthermore, WGCNA analysis identified seven co‐expression modules and super enhancer‐regulated networks orchestrated by transcription factors (RFX2, RFX4) and hub genes (NEAT1, CFLAR). These networks stratified patients into high‐ and low‐risk groups with significant survival differences. Collectively, our findings elucidate the intricate interplay between cellular heterogeneity and super enhancer‐driven gene regulation in glioblastoma, providing a translational framework for targeting oncogenic hubs and modulating microenvironment interactions.